查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1439923

乳癌診斷 - 全球市場考量、競爭格局、市場預測 (2030)

Breast Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: 按訂單生產 | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

全球乳癌診斷市場規模預計到 2023 年將達到 42 億美元，到 2030 年將達到 61.6 億美元，2024-2030 年預測期間複合年增長率為 6.67%。 由於乳癌盛行率增加、人口老化和久坐生活方式增加、技術進步以及政府加大篩檢和診斷率舉措等因素，該市場正在出現積極增長；將在2024-2030年預測期內推動市場增長。

乳癌診斷市場動態

乳癌診斷市場的主要驅動因素之一是全球乳癌發生率的增加。 根據世界衛生組織（WHO）2022年的數據，2020年全球有230萬名女性被診斷出罹患乳癌。 此外，根據同一數據，截至2020年底，過去五年中有780萬活著的女性被診斷出患有乳癌，使其成為世界上最常見的癌症。

因此，全球乳癌盛行率的上升將增加對乳癌診斷的需求，從而推動乳癌診斷市場在預測期內（2024-2030 年）的成長。

此外，推動乳癌診斷市場成長的另一個主要因素是某些國家政府加強提高人們對早期篩檢和診斷的認識。 例如，2022年3月，世衛組織啟動了全球乳癌倡議（GBCI），旨在將全球70歲以下女性乳癌死亡率每年降低2.5%，到2030年降低25%，到2040年降低40% 。防止死於乳癌。 提供有關乳癌徵兆、症狀、早期發現、治療等資訊將使大眾瞭解乳癌的診斷和治療，增加對乳癌診斷市場的需求。

然而，乳癌診斷的高昂成本、誤報等診斷限制以及乳房X光檢查的過度診斷導致不必要的治療可能會減緩乳癌診斷市場的成長。

COVID-19 大流行對乳癌診斷市場產生了輕微的負面影響，因為患有癌症和其他疾病的患者入院時間晚於患有 COVID-19 的患者。Ta。 嚴格的封鎖規定，加上人員短缺以及口罩和個人防護用品套件的短缺，對醫院的乳癌患者收治產生了重大影響。 然而，隨著大眾疫苗接種和醫療部門活動的恢復，乳癌診斷市場已恢復勢頭，預計在預測期內將進一步成長。

乳癌診斷市場區隔分析

就乳癌診斷市場的類型細分而言，透過乳房X光攝影、超音波、乳房MRI、CT掃瞄等影像技術進行診斷預計在預測期內將佔據較大佔有率。 這是由於與診斷影像技術相關的各種好處，例如乳房X光攝影的乳房組織的低劑量X光影像、早期和及時檢測乳癌以及降低接受化療的風險。 例如，根據 2022 年 7 月國家癌症研究所的數據，美國預防工作小組建議 76.4% 的 50 至 74 歲女性在過去兩年內做過乳房 X 光檢查。 至2030年，77.1%的50歲至74歲女性將接受乳癌篩檢。

2022 年 1 月，杜克大學研究人員創建了一個人工智慧平台，該平台可以分析乳房 X 光檢查中是否存在潛在的癌性病變，並確定患者是否應該接受侵入性活檢。 這種人工智慧可以幫助檢測可疑病變，並可用於訓練如何解讀乳房X光檢查影像，幫助醫生做出醫療決策。 此外，這種人工智慧技術可用於做出明智的決策並增加對診斷影像的需求，從而推動2024-2030年預測期內乳癌診斷設備市場的成長。

本報告研究和分析了全球乳癌診斷市場，提供市場規模和預測、驅動因素和挑戰、公司和產品概況等。

目錄

第一章乳癌診斷市場報告簡介

第二章乳癌診斷市場執行摘要

  • 調查範圍
  • 市場概覽
  • 競爭評估

第三章監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第四章乳癌診斷市場主要因素分析

  • 推動乳癌診斷市場的因素
    • 乳癌發生率不斷上升
    • 老年人口增加
    • 技術進步
    • 政府努力提高篩檢和診斷率。
  • 乳癌診斷市場的限制與挑戰
    • 乳癌診斷費用高昂
    • 乳房X光檢查的診斷限制（誤報、過度診斷等）
  • 乳癌診斷市場機遇
    • 免疫療法在乳癌診斷過程中取得良好效果

第五章乳癌診斷市場波特五力分析

第六章COVID-19對乳癌診斷的影響分析

第七章乳癌診斷市場佈局

  • 產品類型
    • 設備
    • 試劑、耗材
  • 依類型
    • 成像
    • 臨床檢查
  • 依最終使用者類型
    • 醫院
    • 診斷實驗室
    • 癌症研究中心
    • 其他
  • 地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他領域

第八章乳癌診斷市場公司及產品概況

  • Niramai Health Analytix
  • UE LifeSciences Inc
  • Xuzhou AKX Electronic Science and Technology Co Ltd
  • Koning Health
  • Kheiron Medical Technologies Limited
  • Technomax Corporation
  • General Electric Company
  • Hologic Inc.
  • Koninklijke Philips N.V
  • Fujifilm Corporation
  • Canon Medical Systems Argentina S.A
  • Hitachi Ltd
  • Carestream Health
  • Planmed Oy
  • SonoCine
  • Siemens Healthcare GmbH
  • Seno Medical
  • Stryker
  • Izotropic Corporation
  • CMR Naviscan

第9章KOL瀏覽量

第 10 章專案方法

第 11 章關於 DelveInsight

第 12 章免責聲明與聯絡我們

Product Code: DIMDCL0604

Breast Cancer Diagnostics Market By Product Type (Instrument, Reagent, And Consumables), By Type (Imaging, Lab Test), By End-User Type (Hospitals, Diagnostic Laboratories, Cancer Research Centers, Others), and by geography is expected to grow at a steady CAGR during the given forecast period owing to increase in the prevalence of breast cancer globally, growing geriatric population, the rising number of government initiatives to increase screening and diagnosis, and the increasing number of technological advancements.

The global Breast Cancer Diagnostics market was valued at USD 4.20 billion in 2023, growing at a CAGR of 6.67% during the forecast period from 2024 to 2030 to reach USD 6.16 billion by 2030. The breast cancer diagnostics market is witnessing positive growth owing to factors such as the increasing prevalence of breast cancer, increasing age and sedentary lifestyle, technological advancements, rising number of government initiatives to increase the rate of screening and diagnosis, thereby driving the growth of the breast cancer diagnostics market during the forecast period from 2024-2030.

Breast Cancer Diagnostics Market Dynamics:

One of the main drivers of the breast cancer diagnostics market is the increasing prevalence of breast cancer globally. As per the World Health Organization (WHO) 2022 data, in 2020 breast cancer was diagnosed in 2.3 million women globally. Further, as per the same source by the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the last 5 years, making it the world's most prevalent cancer.

Therefore, an increase in the prevalence of breast cancer around the world would lead to an increase in the demand for breast cancer diagnostics, thereby propelling the growth of the breast cancer diagnostics market during the forecast period (2024-2030).

Moreover, another key factor that is responsible for the growth of the breast cancer diagnostics market is the rising number of initiatives taken by specific national governments to increase awareness about early screening and diagnosis. For instance, in March 2022, WHO launched a Global Breast Cancer Initiative (GBCI) to reduce global breast cancer mortality by 2.5% per year, which would prevent 25% of breast cancer deaths by 2030 and 40% by 2040 among women under 70 years of age. Providing information about signs, symptoms, early detection, treatment, etc. of breast cancer would aware public of breast cancer diagnosis and treatment which would increase the demand for the breast cancer diagnostics market.

However, the high cost of diagnosis of breast cancer, limitations in diagnosis like false-positive results, and overdiagnosis with mammogram leads to unnecessary treatments which can slow down the breast cancer diagnostics market growth.

The COVID-19 pandemic has slightly impacted the market for breast cancer diagnostics market negatively as hospital admissions for patients suffering from cancers and other disorders were not a priority in comparison to the patients suffering from coronavirus. Along with strict lockdown regulations, a lack of staff, and a shortage of masks and PPE kits made a huge impact on breast cancer patient admissions in hospitals. However, with the masses being vaccinated and the resumption of activities in the healthcare sector, the breast cancer diagnostics market has picked momentum and is expected to further grow during the forecast period.

Breast Cancer Diagnostics Market Segment Analysis:

Breast cancer diagnostics market by product type (instrument, reagent, and consumables), type (imaging, lab test), end-user type (hospitals, diagnostic laboratories, cancer research centers, others), and by geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the type segment of the breast cancer diagnostics market, diagnosis through imaging techniques such as mammography, ultrasound, breast MRI, and CT scan is expected to hold a significant share during the forecast period, owing to the various benefits associated with them such as low-dose x-ray image of breast tissue through a mammogram, early and timely detection of breast cancer, thereby also reducing the risks of undergoing chemotherapy. For example, according to the National Cancer Institute July 2022, U.S. preventive task force recommends that 76.4% of women aged 50-74 years had mammography within the past 2 years. By 2030, 77.1 % proportion of women aged 50-74 years would have received breast cancer screening.

In addition, in January 2022, Duke University researchers created an Artificial Intelligence (AI) platform to analyze potentially cancerous lesions in mammography scans and determine whether patients should receive invasive biopsies. This AI helped to detect suspicious lesions that could be used to train students on how to read mammography images and can help physicians to take health care decisions. Furthermore, this AI technology could be used for making wise decisions, increasing the demand for image diagnosis, thus driving the growth of the breast cancer diagnostics devices market during the forecast period from 2024-2030.

North America is expected to dominate the overall Breast Cancer Diagnostics Market:

Among all the regions, North America is expected to dominate the global breast cancer diagnostics market during the forecast period from 2024-2030. Factors such as aging, race, and ethnicity drive breast cancer which increase the demand for breast cancer diagnostics in the North America market.

According to the American Cancer Society (2023), in January 2022 in the US, variations in breast cancer could be seen due to differences in racial and ethnic groups. The age of diagnosis was slightly younger for black women (age 60), followed by white women (age 63). Black women also have a higher death rate in this as 1 in 5 black women have triple-negative breast cancer which was more than in any other racial/ethnic group.

Furthermore, aging is the biggest risk factor for breast cancer. As people grow older, the chances of developing cancer increase. According to the same source in February 2022, 1 out of 8 women younger than 45 developed invasive breast cancer, and 2 out of 3 invasive breast cancers were found in women 55 or older.

The Breast Cancer Organization (2023) also mentioned that as of January 2022, more than 3.8 million women had a history of breast cancer in the US. One in eight American women (13%) was expected to develop invasive breast cancer at some point in their lives on average. In men, 2,710 new cases of invasive breast cancer are expected to be diagnosed by 2022 end in the US.

Therefore, the rising prevalence of breast cancer, aging, race, and ethnicity would result in the rising demand for breast cancer diagnostics which in turn would provide a conducive growth environment for the North America breast cancer diagnostics market.

Breast Cancer Diagnostics Market Key Players:

Some of the key market players operating in the breast cancer diagnostics market include Niramai Health Analytix, UE LifeSciences Inc, Xuzhou AKX Electronic Science And Technology Co Ltd, Kheiron Medical Technologies Limited, Technomax Corporation, General Electric Company, Hologic Inc, Koninklijke Philips N.V, Fujifilm Corporation, Canon Medical Systems Argentina S.A, Hitachi Ltd, Carestream Health, Planmed Oy, SonoCine, Seno Medical, Stryker, Izotropic Corporation, Koning Health, Siemens Healthcare GmbH, CMR Naviscan, among others.

Recent Developmental Activities in the Breast Cancer Diagnostics:

In March 2022, Niramai received US FDA clearance for their first medical device, SMILE-100 System (breast thermography device).

In Jan 2022, UE LifeSciences entered into a definitive distribution agreement with Siemens Healthineers, adding its flagship device iBreastExam to Siemens' 360-degree breast care product portfolio for the U.S. market.

In Nov 2022, Kheiron Medical Technologies Launched RSViP to Help U.S. Breast Screening Programs Tackle Backlogs Worsened by COVID-19.

In Jan 2022, Kheiron's AI Breast Screening Solution Mia Receives Regulatory Clearance in Australia and New Zealand.

Key Takeaways from the Breast Cancer Diagnostics Market Report Study

  • Market size analysis for current breast cancer diagnostics market size (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching breast cancer diagnostics.
  • Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
  • Key companies dominating the global breast cancer diagnostics.
  • Various opportunities are available for other competitors in the breast cancer diagnostics market space.
  • What are the top-performing segments in 2023? How these segments will perform in 2030.
  • Which are the top-performing regions and countries in the current breast cancer diagnostics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for breast cancer diagnostics market growth in the coming future?

Target Audience who can be benefited from this Breast Cancer Diagnostics Market Report Study

  • Breast cancer diagnostics products providers
  • Research organizations and consulting companies
  • Breast cancer diagnostics-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in Breast cancer diagnostics
  • Various End-users who want to know more about the Breast cancer diagnostics Market and the latest technological developments in Breast cancer diagnostics.

Frequently Asked Questions for Breast Cancer Diagnostics:

1. What are breast cancer diagnostics?

Breast cancer diagnostics are used detect breast cancer in men and women experiencing its signs and symptoms. Early diagnosis could improve cancer treatment by providing care at the earliest stage possible.

2. What is the market for Global breast cancer diagnostics?

The global Breast Cancer Diagnostics market was valued at USD 4.20 billion in 2023, growing at a CAGR of 6.67% during the forecast period from 2024 to 2030 to reach USD 6.16 billion by 2030.

3. What are the drivers for the Global breast cancer diagnostics Market?

The breast cancer diagnostics market is witnessing positive market growth owing to the factors such as, increasing prevalence of breast cancer, Increasing age and sedentary lifestyle, inherited breast cancer genes, race, ethnicity, technological advancements, and government initiatives to increase the rate of screening and diagnosis.

4. Who are the key players operating in the breast cancer diagnostics Market?

Some of the key market players operating in the breast cancer diagnostics market include Niramai Health Analytix, UE LifeSciences Inc, Xuzhou AKX Electronic Science And Technology Co Ltd, Kheiron Medical Technologies Limited, Technomax Corporation, General Electric Company, Hologic Inc, Koninklijke Philips N.V, Fujifilm Corporation, Canon Medical Systems Argentina S.A, Hitachi Ltd, Carestream Health, Planmed Oy, SonoCine, Seno Medical, Stryker, Izotropic Corporation, Koning Health, Siemens Healthcare GmbH, CMR Naviscan, among others.

5. Which region has the highest share in the breast cancer diagnostics Market?

North America is expected to dominate the global breast cancer diagnostics market. Factors contributing to its growth are the increasing prevalence of breast cancer due to aging, race, ethnicity, and others, increasing the demand for breast cancer diagnostics, thus driving the breast cancer diagnostics market growth in North America region.

Table of Contents

1.Breast Cancer Diagnostics Market Report Introduction

2.Breast Cancer Diagnostics Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment

3. Regulatory Analysis

  • 3.1. The US
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Breast Cancer Diagnostics Market Key Factors Analysis

  • 4.1. Breast Cancer Diagnostics Market Drivers
    • 4.1.1. Increasing Prevalence of Breast Cancer
    • 4.1.2. Rising Geriatric Population
    • 4.1.3. Technological Advancements
    • 4.1.4. Government Initiatives to Increase the Rate of Screening and Diagnosis.
  • 4.2. Breast Cancer Diagnostics Market Restraints And Challenges
    • 4.2.1. High Cost Of Diagnosis Of Breast Cancer
    • 4.2.2. Limitation In Diagnosis Like In Mammogram Like False-Positive Results And Overdiagnosis
  • 4.3. Breast Cancer Diagnostics Market Opportunities
    • 4.3.1. Immunotherapy yielding positive results during breast cancer diagnosis

5. Breast Cancer Diagnostics Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Breast Cancer Diagnostics

7. Breast Cancer Diagnostics Market Layout

  • 7.1. By Product Type
    • 7.1.1. Instruments
    • 7.1.2. Reagent and Consumables
  • 7.2. By Type
    • 7.2.1. Imaging
    • 7.2.2. Lab test
  • 7.3. By End User Type
    • 7.3.1. Hospitals
    • 7.3.2. Diagnostic Laboratories
    • 7.3.3. Cancer Research Centers
    • 7.3.4. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. North America Breast Cancer Diagnostics Market, by Country
      • 7.4.1.1.1. US Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.1.1.2. Canada Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.1.1.3. Mexico Breast Cancer Diagnostics Market in USD million (2021-2030)
    • 7.4.2. Europe
      • 7.4.2.1. Europe Breast Cancer Diagnostics Market, by Country
      • 7.4.2.1.1. France Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.2.1.2. Germany Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.2.1.3. United Kingdom Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.2.1.4. Italy Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.2.1.5. Spain Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.2.1.6. Rest of Europe Breast Cancer Diagnostics Market in USD million (2021-2030)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. Asia-Pacific Breast Cancer Diagnostics Market, by Country
      • 7.4.3.1.1. China Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.3.1.2. Japan Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.3.1.3. India Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.3.1.4. Australia Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.3.1.5. South Korea Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.3.1.6. Rest of Asia Pacific Breast Cancer Diagnostics Market in USD million (2021-2030)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. RoW Breast Cancer Diagnostics Market, by Region
      • 7.4.4.1.1. Middle East Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.4.1.2. Africa Breast Cancer Diagnostics Market in USD million (2021-2030)
      • 7.4.4.1.3. South America Breast Cancer Diagnostics Market in USD million (2021-2030)

8. Breast Cancer Diagnostics Market Company and Product Profiles

  • 8.1. Niramai Health Analytix
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. UE LifeSciences Inc
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Xuzhou AKX Electronic Science and Technology Co Ltd
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Koning Health
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Kheiron Medical Technologies Limited
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Technomax Corporation
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. General Electric Company
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Hologic Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Koninklijke Philips N.V
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Fujifilm Corporation
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Canon Medical Systems Argentina S.A
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Hitachi Ltd
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Carestream Health
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Planmed Oy
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. SonoCine
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. Siemens Healthcare GmbH
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Seno Medical
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Stryker
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Izotropic Corporation
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. CMR Naviscan
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis
  • Table 3: Breast Cancer Diagnostics Market in Global (2021-2030)
  • Table 4: Breast Cancer Diagnostics Market in Global by Product Type (2021-2030)
  • Table 5: Breast Cancer Diagnostics Market in Global by Type (2021-2030)
  • Table 6: Breast Cancer Diagnostics Market in Global by End-user (2021-2030)
  • Table 7: Breast Cancer Diagnostics Market in Global by Geography (2021-2030)
  • Table 8: Breast Cancer Diagnostics Market in North America (2021-2030)
  • Table 9: Breast Cancer Diagnostics Market in North America by Country (2021-2030)
  • Table 10: Breast Cancer Diagnostics Market in the US (2021-2030)
  • Table 11: Breast Cancer Diagnostics Market in Canada (2021-2030)
  • Table 12: Breast Cancer Diagnostics Market in Mexico (2021-2030)
  • Table 13: Breast Cancer Diagnostics Market in Europe (2021-2030)
  • Table 14: Breast Cancer Diagnostics Market in Europe by Country (2021-2030)
  • Table 15: Breast Cancer Diagnostics Market in France (2021-2030)
  • Table 16: Breast Cancer Diagnostics Market in Germany (2021-2030)
  • Table 17: Breast Cancer Diagnostics Market in the United Kingdom (2021-2030)
  • Table 18: Breast Cancer Diagnostics Market in Italy (2021-2030)
  • Table 19: Breast Cancer Diagnostics Market in Spain (2021-2030)
  • Table 20: Breast Cancer Diagnostics Market in the Rest of Europe (2021-2030)
  • Table 21: Breast Cancer Diagnostics Market in APAC (2021-2030)
  • Table 22: Breast Cancer Diagnostics Market in APAC by Country (2021-2030)
  • Table 23: Breast Cancer Diagnostics Market in China (2021-2030)
  • Table 24: Breast Cancer Diagnostics Market in Japan (2021-2030)
  • Table 25: Breast Cancer Diagnostics Market in India (2021-2030)
  • Table 26: Breast Cancer Diagnostics Market in Australia (2021-2030)
  • Table 27: Breast Cancer Diagnostics Market in South Korea (2021-2030)
  • Table 28: Breast Cancer Diagnostics Market in Rest of APAC (2021-2030)
  • Table 29: Breast Cancer Diagnostics Market in the Rest of the World (2021-2030)
  • Table 30: Breast Cancer Diagnostics Market in RoW by Region (2021-2030)
  • Table 31: Breast Cancer Diagnostics Market in the Middle East (2021-2030)
  • Table 32: Breast Cancer Diagnostics Market in Africa (2021-2030)
  • Table 33: Breast Cancer Diagnostics Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis
  • Figure 3: Breast Cancer Diagnostics Market in Global (2021-2030)
  • Figure 4: Breast Cancer Diagnostics Market in Global by Product Type (2021-2030)
  • Figure 5: Breast Cancer Diagnostics Market in Global by Type (2021-2030)
  • Figure 6: Breast Cancer Diagnostics Market in Global by End-user (2021-2030)
  • Figure 7: Breast Cancer Diagnostics Market in Global by Geography (2021-2030)
  • Figure 8: Breast Cancer Diagnostics Market in North America (2021-2030)
  • Figure 9: Breast Cancer Diagnostics Market in North America by Country (2021-2030)
  • Figure 10: Breast Cancer Diagnostics Market in the US (2021-2030)
  • Figure 11: Breast Cancer Diagnostics Market in Canada (2021-2030)
  • Figure 12: Breast Cancer Diagnostics Market in Mexico (2021-2030)
  • Figure 13: Breast Cancer Diagnostics Market in Europe (2021-2030)
  • Figure 14: Breast Cancer Diagnostics Market in Europe by Country (2021-2030)
  • Figure 15: Breast Cancer Diagnostics Market in France (2021-2030)
  • Figure 16: Breast Cancer Diagnostics Market in Germany (2021-2030)
  • Figure 17: Breast Cancer Diagnostics Market in the United Kingdom (2021-2030)
  • Figure 18: Breast Cancer Diagnostics Market in Italy (2021-2030)
  • Figure 19: Breast Cancer Diagnostics Market in Spain (2021-2030)
  • Figure 20: Breast Cancer Diagnostics Market in the Rest of Europe (2021-2030)
  • Figure 21: Breast Cancer Diagnostics Market in APAC (2021-2030)
  • Figure 22: Breast Cancer Diagnostics Market in APAC by Country (2021-2030)
  • Figure 23: Breast Cancer Diagnostics Market in China (2021-2030)
  • Figure 24: Breast Cancer Diagnostics Market in Japan (2021-2030)
  • Figure 25: Breast Cancer Diagnostics Market in India (2021-2030)
  • Figure 26: Breast Cancer Diagnostics Market in Australia (2021-2030)
  • Figure 27: Breast Cancer Diagnostics Market in South Korea (2021-2030)
  • Figure 28: Breast Cancer Diagnostics Market in Rest of APAC (2021-2030)
  • Figure 29: Breast Cancer Diagnostics Market in the Rest of the World (2021-2030)
  • Figure 30: Breast Cancer Diagnostics Market in RoW by Region (2021-2030)
  • Figure 31: Breast Cancer Diagnostics Market in the Middle East (2021-2030)
  • Figure 32: Breast Cancer Diagnostics Market in Africa (2021-2030)
  • Figure 33: Breast Cancer Diagnostics Market in South America (2021-2030)
  • Figure 34: Market Drivers
  • Figure 35: Market Barriers
  • Figure 36: Marker Opportunities
  • Figure 37: PORTER'S Five Force Analysis